Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Deloitte
Covington
Medtronic
Cipla
Harvard Business School
Johnson and Johnson
US Department of Justice
Julphar

Generated: June 19, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,475,034

« Back to Dashboard

Summary for Patent: 5,475,034
Title: Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
Abstract:Novel ester and amide derivatives of 3-benzoylphenylacetic acid are disclosed. The use of these novel derivatives and certain known derivatives in topically administrable compositions for the treatment of ophthalmic inflammatory disorders is also disclosed.
Inventor(s): Yanni; John M. (Burleson, TX), Graff; Gustav (Cleburne, TX), Hellberg; Mark R. (Arlington, TX)
Assignee: Alcon Laboratories, Inc. (Fort Worth, TX)
Application Number:08/254,090
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,475,034
Patent Claims: 1. A method of treating ophthalmic inflammatory disorders and ocular pain which comprises topically administering to the eye a pharmaceutical composition comprising an anti-inflammatory-effective amount of a 3-benzoylphenylacetic acid derivative of the formula: ##STR7## R=H, C.sub.1-4 (un)branched alkyl, CF.sub.3, or SR.sup.4, Y=NR"R',

R'=H, or C.sub.1-10 (un)branched alkyl, (un)substituted (substitution as defined by X below),

R"=H,

X and X' independently=H, F, Cl, Br, I, OR', OH, SR.sup.4, CF.sub.3, R.sup.4, or NO.sub.2,

R.sup.4 =C.sub.1-6 (un)branched alkyl,

m=0-3,

m'=0-5, and

W=H.

2. The method of claim 1 wherein the 3-benzoylphenylacetic acid derivative is of the formula: ##STR8## R=H, or C.sub.1-2 alkyl Y=NR'R",

R'=H, or C.sub.1-6 (un)branched alkyl,

X and X' independently=H, F, Cl, Br, CF.sub.3, OR', SR.sup.4, or R.sup.4,

R"=H,

R.sup.4 =C.sub.1-4 (un)branched alkyl,

m=0-2,

m'=0-2, and

W=H.

3. The method of claim 1 wherein the 3-benzoylphenylacetic acid derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-.alpha.-(n-propylthio)-phenylacetamide, 2-Amino-3-benzoly-.alpha.-(n-propylthio)-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)-.alpha.-(n-propylthio)-phenylacetamide, 2-Amino-3-benzoyl-5-chloro-.alpha.-(methylthio)-phenylacetamide, 2-Amino-3-(4-fluorobenzoyl)-.alpha.-(methylthio)-N-(2-methozy)ethylacetami de, 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-5-chlorophenylacetamide, 2-Amino-3-(4-fluorobenzoyl)-N-(2-methoxy)ethyl phenylacetamide, 2-Amino-3-(4-bromobenzoyl)-phenylacetamide, and 2-Amino-3-(4-bromobenzoyl)-N-methyl phenylacetamide.

4. The method claim 3 wherein the 3-benzoylphenylacetic acid derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-.alpha.-(n-propylthio)-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)-.alpha.-(n-propylthio)-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)-.alpha.-(n-propylthio)-phenylacetamide, 2-Amino-3-benzoyl-5-chloro-.alpha.-(methylthio)-phenylacetamide, 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-5-chlorophenylacetamide, and 2-Amino-3-(4-bromobenzoyl)-phenylacetamide.

5. The method of claim 4 wherein the 3-benzoylphenylacetic acid derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-phenylacetamide and 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide.

6. The method of claim 1 wherein the amount of 3-benzoylphenylacetic acid is from about 0.001 to about 4.0% (w/v).

7. The method of claim 6 wherein the amount of 3-benzoylphenylacetic acid is from about 0.01 to about 0.5% (w/v).

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Colorcon
Cantor Fitzgerald
Fuji
Healthtrust
Accenture
AstraZeneca
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.